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ABSTRACT: A targeted reversed-phase gradient UPLC-MS/MS assay has been developed for the quantiﬁcation /monitoring of
66 amino acids and amino-containing compounds in human plasma and serum using precolumn derivatization with 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate (AccQTag Ultra). Derivatization of the target amines required minimal sample
preparation and resulted in analytes with excellent chromatographic and mass spectrometric detection properties. The resulting
method, which requires only 10 μL of sample, provides the reproducible and robust separation of 66 analytes in 7.5 min,
including baseline resolution of isomers such as leucine and isoleucine. The assay has been validated for the quantiﬁcation of 33
amino compounds (predominantly amino acids) over a concentration range from 2 to 20 and 800 μM. Intra- and interday
accuracy of between 0.05 and 15.6 and 0.78−13.7% and precision between 0.91 and 16.9% and 2.12−15.9% were obtained. A
further 33 biogenic amines can be monitored in samples for relative changes in concentration rather than quantiﬁcation.
Application of the assay to samples derived from healthy controls and patients suﬀering from acetaminophen (APAP,
paracetamol)-induced acute liver failure (ALF) showed signiﬁcant diﬀerences in the amounts of aromatic and branched chain
amino acids between the groups as well as a number of other analytes, including the novel observation of increased
concentrations of sarcosine in ALF patients. The properties of the developed assay, including short analysis time, make it suitable
for high-throughput targeted UPLC-ESI-MS/MS metabonomic analysis in clinical and epidemiological environments.
Untargeted metabolic phenotyping (metabotyping1,2) asperformed in metabonomic/metabolomic studies oﬀers
the possibility of discovering new biomarkers.3,4 The use of LC-
MS-based techniques for this purpose is now widespread5−7
with an increasingly role evident in biomarker discovery in
large-scale epidemiological and personalized medicine studies
(e.g.8−12). However, as is widely appreciated, untargeted
methods generally provide relative changes (fold changes) for
metabolites, rather than absolute concentration data. In
addition, despite the application of, for example, high-resolution
UHPLC separations and the use of combinations of separation
techniques (particularly reversed-phase and HILIC modes of
chromatography12) for sample analysis, the coverage of the
metabolome remains far from comprehensive. A consequence
of this partial, and qualitative, coverage is there is a need for
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subsequent further validation of the changes detected by
untargeted methods. For example, a recent study of plasma
amino acid proﬁles in renal transplant patients compared the
results obtained using both an untargeted metabolic proﬁling
method against a speciﬁc LC-MS/MS assay showing that, while
there was overlap between the data obtained by both methods,
there were also signiﬁcant diﬀerences.13 Use of a validated
targeted assay, based on optimized sample preparation and
bespoke LC-MS conditions, combined with appropriate
internal standards, enables quantitative data to be obtained
for the analytes of interest, which is especially valuable in
clinical biomarker discovery. In addition, compounds related to
the target analytes that may not have been detected in the
original metabotyping study can also be determined. Amino
acids, and amino-containing compounds, are modulated in
many diﬀerent conditions (e.g., toxicity, cancer, metabolic
diseases, etc.) and often vary in epidemiological or clinical
metabolic phenotyping studies. As such, amino compounds
represent an obvious class of compounds for targeted analysis.
There are of course innumerable methods for the analysis of
complex mixtures of amino acids and biogenic amines (dating
back to the pioneering work of, e.g., Martin14 and Dent15 and
their co-workers using 2D paper chromatography). Currently
many quantitative methods for amino compounds use MS for
detection (reviewed in refs 16,17) including those based on e.g.,
GC-MS,18,19 CE-MS/MS,20,21 and LC-MS/MS.22−44 However,
for reversed-phase (RP) LC-based methods, the amphoteric
nature of the amino acids often results in poor retention,
making direct analysis impractical for all but a few analytes.
Alternative modes of LC that improve retention allowing direct
analysis include separations based on strong cation exchange,22
HILIC,23,24 or ion-pairing.25−32 However, such approaches are
not without disadvantages and, as a result, many methods rely
on forming derivatives of amino compounds that enable RPLC
to be performed. A number of reagents are available for the
derivatization of amino acids to facilitate analysis by LC-
MS.33−44 One of these, 6-aminoquinolyl-N-hydroxysuccinimid-
yl carbamate (AccQTag Ultra), originally applied to the
determination of primary and secondary amines via ﬂuo-
rescence detection, for example,45−49 has also been employed
for sensitive and speciﬁc LC-MS detection.41−44 Here a high-
throughput, sensitive, and selective UPLC-ESI-MS/MS assay
for the targeted analysis of amino acids and biogenic amines in
human plasma or serum based on the AccQTag Ultra reagent is
described. This method forms one of a suite of targeted50,51 and
untargeted12 methods developed, or under development, to
support metabolic phenotyping and biomarker validation for
the MRC-NIHR National Phenome Centre. The method was
applied to samples obtained from healthy controls and patients
suﬀering from acute liver failure (ALF) resulting from
acetaminophen (APAP, paracetamol) overdose.
■ EXPERIMENTAL SECTION
Chemicals and Reagents. Analyte standards (listed in
Table 1) were from Sigma-Aldrich (Gillingham, U.K.).
Isotopically labeled amino acids for use as internal standards
(IS) (see Table 1) were from Cambridge Isotope Laboratories
(MA, U.S.A.) or QMX Laboratories (Essex, U.K.) (see Table
S9 caption for details). Optima grade water was obtained from
Fisher Scientiﬁc (Leicester, U.K.), LC-MS grade solvents and
formic acid were from Sigma-Aldrich (Gillingham, U.K.) and
the AccQTag Ultra reagent from Waters Corporation (Milford,
MA, U.S.A.).
Samples. Plasma samples were obtained from 14 patients
with acetaminophen-induced acute liver failure (ALF) (2 male,
12 female; 19 to 56 (mean = 38) years of age) and 40 healthy
volunteers (20 male, 20 female; 32−41 (mean = 37) years of
age) as controls. A Mann U Whitney test found that the ages of
the subjects in the control and APAP-induced ALF groups were
well matched (p-value = 0.2103). Local national research ethics
service (NRES) approval was obtained for this study and
patients, or their nominee, provided written informed consent
within 24 h of admission to Kings College Hospital London.
Blood samples were obtained within 24 h of admission into BD
Vacutainer lithium heparin-containing vacuum tubes (Franklin
Lakes, NJ). Plasma was obtained by centrifugation (12 000g, 4
°C, 10 min.) within 1 h of sample collection and was then
stored at −80 °C.
Analytical Procedure. Preparation of Stock Solutions.
Calibration and QC samples were prepared from a standard
mixture of neutral, basic, and acidic physiological amino acids
(Sigma-Aldrich) with the addition of asparagine and glutamine
on each day of the validation. Duplicate working stock solutions
(A and B) were made in 50:50 water/methanol (v/v) at a
concentration of 400 μM for each analyte. Dilutions of stock A
were used to prepare calibration standards and dilutions of
stock B for QC samples. For validation, 16 compounds were
quantiﬁed against stable-isotope-labeled internal standards with
17 validated using a surrogate internal standard (see Table 1).
Calibration, Quality Control (QC), and Stable-Isotope-
Labeled (SIL) IS Solutions. Calibration standards were prepared
by dilution with 50:50 water/methanol (v/v) to give
concentrations of 0, 1, 2, 4, 10, 20, 40, 100, 200, and 400
μM. QC samples were prepared by dilution with 50:50 water/
methanol (v/v) to provide concentrations at the lower limit of
quantiﬁcation (LLOQ) (1, 3, or 10 μM depending upon the
analyte), low-level (3, 10, or 30 μM depending upon the
analyte), midlevel QC (30 or 150 μM depending on the
analyte), high-level (300 μM), and upper limit of quantiﬁcation
(400 μM) of each amino acid. Solutions of each SIL amino acid
(1 mg/mL) in Optima grade water were combined to provide a
stock solution at a concentration of 10 μg/mL. A 20 μL aliquot
of each calibration and QC standard were transferred to an
Eppendorf tube followed by 5 μL of the IS solution (IS was not
added to the blanks), and 40 μL of cold isopropanol (IPA)
containing 1% formic acid (v/v). After 20 min at −20 °C
samples were centrifuged (13 000g, 10 min) and 10 μL of
supernatant transferred to a glass HPLC vial (or 96-well plate)
for derivatization.
Sample Preparation. Human plasma or serum samples were
left to thaw at 4 °C, and then 10 μL of each sample was
transferred to an Eppendorf tube to which 10 μL of Optima
grade water was added then 5 μL of the 10 μg/mL IS mixture.
Proteins were then precipitated using 40 μL of cold isopropanol
(plus 1% formic acid (v/v)) with vortex mixing. After 20 min at
−20 °C, samples were centrifuged 13 000g, 10 min), and then
10 μL of the supernatant was transferred to a glass HPLC vial
(or 96-well plate) for derivatization as described below.
Derivatization. For derivatization, 1 mL of acetonitrile was
added to the AccQTag Ultra reagent powder, vortex mixed, and
dissolved by heating at 55 °C (no longer than 15 min). Then,
70 μL of borate buﬀer (pH 8.6) was added to the samples (with
vortex mixing) followed by 20 μL of AccQTag Ultra
derivatizing reagent solution, with further vortex mixing, and
heating at 55 °C (10 min). Samples were then diluted 1:100
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with Optima grade water for analysis. Sample preparation is
summarized in Supplementary Table S1
UHPLC-MS/MS Analyses. UHPLC-MS/MS analysis was
performed using an Acquity UPLC binary solvent manager,
sampler manager, and column manager (Waters, Milford, MA,
U.S.A.) interfaced with a Xevo TQ-S tandem quadrupole mass
spectrometer (Waters, Wilmslow, U.K.). MS/MS Detection
was via electrospray ionization (ESI) in positive ion mode using
multiple reaction monitoring (MRM) for the quantiﬁcation of
each compound (see Table 1) (MS conditions for each analyte
were determined via direct infusion of individual derivatives).
Nitrogen was used as the desolvation gas, and argon was used
as the collision gas. The following generic source conditions
were used: capillary voltage, 1.5 kV; source oﬀset, 50 V;
desolvation temperature, 600 °C; source temperature, 150 °C,
desolvation gas ﬂow, 1000 L/h; cone gas ﬂow, 150 L/h;
nebulizer gas, 7.0 bar; collision gas, 0.15 mL/min. Compound-
speciﬁc parameters are detailed in Table 1.
The chromatographic separation used reversed-phase gra-
dient chromatography on a HSS T3 2.1 × 150 mm, 1.8 μm
column (Waters). The mobile phase was composed of 0.1%
formic acid in water (v/v) (A) and 0.1% formic acid in
acetonitrile (v/v) (B). The column temperature was main-
tained at 45 °C and linear gradient elution was performed at 0.6
mL/min starting at 4% B, held for 0.5 min before increasing to
10% over 2 min, then to 28% over 2.5 min, and ﬁnally
increasing to 95% for 1 min, before returning to 4% B (1.3
min) for re-equilibration. The weak and the strong washes were
95:5 water/acetonitrile (v/v) and 100% isopropanol, respec-
tively.
Before analysis, injections (2 μL) of a double blank were
performed to ensure system stability and cleanliness followed
by a “system suitability test”, performed by injecting the low-
level QC sample containing all the standards and internal
standards. After the injection of a further double blank and a
single blank, analysis was started with injections of the
calibration curve (low concentrations to high) followed by a
double blank injection. The QC standards (at least 6 QC
samples, 2 at each level) were interspersed evenly throughout
the study samples as shown in Figure 1. Study samples were
randomized prior to sample preparation to minimize bias due
to batch eﬀects. Following analysis of all of the samples in the
batch, a second set of calibration samples were injected, again
using the sequence of low to high concentrations.
Method Validation. Method validation for the method was
based as far as practicable on the FDA “Guidance for Industry”
on Bioanalytical methods.52
Intra- and Inter-Assay Precision. To determine assay
precision calibration standards prepared from stock A and 6-
fold replicates from stock B at the same concentration as six of
the calibration standards were analyzed as QC samples, in a
single batch using the methods described. Linearity was
assessed using the R2 correlation coeﬃcient determined from
calibration standards was required to be >0.99 over the 3 days
of the validation.
The intra-assay variability of the method was determined
using the CV for replicate assays (n = 6) for each of the six
selected concentrations on a single occasion. Interassay
precision was assessed on three separate days using six QC
samples at three concentrations assayed together with a set of
calibration standards and biological samples and determined as
the CV for each set of the QC samples (n = 18).52 To be
accepted, a minimum of 67% of the QC standards must have
had a deviation of no more than 15% from their nominal
concentration, with at least 50% of the QC injections at each
concentration meeting this criterion.
Speciﬁcity. Human plasma and serum from six diﬀerent
subjects were tested to determine matrix interferences using
stable-isotope-labeled analogues.
Carryover. Carryover was assessed with a double blank run
immediately after an ULOQ calibration standard and was
accepted if the response was ≤20% of the average response
from the LLOQ standards. Carryover for the IS was acceptable
if the response in the double blank sample that was ≤5% of the
average response from the calibration standards (including the
single blank).
Recovery. In the absence of analyte free matrix, recovery
from plasma/serum from six sources was estimated using
stable-isotope-labeled (SIL) compounds. Recovery was calcu-
lated by comparing the responses for six replicates of extracted
samples spiked at 1 μg/mL (0.24−0.67 μM depending on the
analyte) and at 3 μM, with replicates of extracted blank matrix
to which SIL(s) were added postextraction, at the same
nominal concentrations.
Matrix Interferences. Matrix-to-analyte interferences were
assessed by analyzing six double blanks for responses at the
retention times of the analytes compared to the mean of the
analyte responses in the LLOQ calibration standards. A
minimum of ﬁve of the six double blanks had to be less than
20% of the signal in the LLOQ calibration standard. Matrix
eﬀects on the SIL ISs were assessed using the same approach
with the acceptance criteria based on signals being less than 5%
of the average IS response of the standards in the calibration
curve in at least ﬁve of the six double blanks. For analyte to
analyte interference aliquots of the same lot of blank matrix
were spiked with each analyte, in triplicate, at the same
concentration as the highest concentration standard and
analyzed to assess their potential interference at the retention
time of the other analytes. Interference was considered to be
present if a response ≥20% to that of another analyte was
detected for the LLOQ standard. For analyte to IS interference,
the blank matrix was spiked with analytes at the concentration
of the highest concentration standard and responses at the
retention time of the IS were compared to the average response
of the IS of all standards accepted in the calibration curve
Figure 1. Sequence of analysis for amino acid quantiﬁcation of randomized samples bracketed by calibration standards and interspersed with QC
injections.
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Table 1. Chromatographic and Mass Spectrometric Characteristics of the Analytesa
no. compound parent (m/z) fragment (m/z) RT (min) dwell time (s) cone voltage (V) collision energy (eV) LLOQ (μM)a
1 creatinine 227.0 158.9 0.51 0.024 30 6 -
2 creatine 302.1 112.1 0.61 0.024 62 20 -
3 galactosamine 350.1 171.1 0.81 0.024 30 32 -
A histidine-d3 329.1 159.1 1.53 0.011 20 10 n/a
4 histidine 326.1 156.1 1.55 0.011 20 10 6
5 N-methyl-L-phenylalanine 351.1 207.0 1.56 0.013 30 24 n/q
6 phosphoserine*A 356.1 171.1 1.61 0.013 20 18 n/q
7 methylamine 202.1 171.1 1.63 0.010 30 16 -
8 3-methylhistidine*A 340.1 170.1 1.73 0.009 30 18 20
9 4-hydroxyproline*C 302.0 171.1 1.75 0.011 10 22 2
10 1-methylhistidine*A 340.1 124.2 1.84 0.009 30 28 20
11 asparagine*D 303.1 171.1 1.97 0.009 30 22 2
12 carnosine*C 397.1 227.2 1.99 0.009 30 14 20
13 arginine 345.1 70.1 2.09 0.009 30 36 20
14 anserine 411.2 241.1 2.03 0.009 68 18 -
B arginine-13C6 351.2 181.2 2.15 0.009 6 18 n/a
15 glycylglycine 303.1 171.1 2.15 0.009 30 22 -
16 taurine*B 296.1 116.3 2.18 0.009 30 60 n/q
C glutamine-d5 322.1 171.1 2.26 0.009 30 24 n/a
17 glutamine 317.1 171.1 2.26 0.009 30 24 2
D serine-d3 279.1 171.1 2.28 0.009 30 20 n/a
18 serine 276.1 171.1 2.28 0.009 30 20 6
19 homoserine*C 290.1 171.1 2.42 0.013 10 18 n/q
20 ethanolamine*D 232.1 171.1 2.43 0.011 10 20 2
E glycine-d5 248.1 171.0 2.56 0.011 30 20 n/a
21 glycine 246.1 116.1 2.56 0.011 30 40 20
22 aspartic acid 304.1 171.1 2.65 0.011 30 22 2
F aspartic acid-d3 307.0 171.1 2.66 0.011 30 20 n/a
23 citrulline*D 346.2 171.1 2.75 0.011 30 26 6
24 sarcosine*F 260.1 171.1 2.82 0.011 30 20 2
G glutamic acid-d3 321.0 171.0 2.93 0.011 30 20 n/a
25 glutamic acid 318.1 171.1 2.94 0.011 30 22 2
26 3-aminopropanoic acid*G 260.1 171.1 3.04 0.011 30 20 n/q
27 threonine 290.1 171.1 3.07 0.018 30 20 2
H threonine-13C4,15N 295.1 171.0 3.13 0.024 30 26 n/a
28 ophthalmic acid 460.3 171.0 3.40 0.011 48 36 -
I alanine-d3 263.1 171.0 3.43 0.011 30 16 n/a
29 alanine 260.1 116.1 3.43 0.011 30 44 2
30 allantoin 329.0 171.1 3.43 0.011 30 20 -
31 4-aminobutyric acid (GABA)*J 274.1 171.1 3.50 0.009 10 20 6
32 aminoadipic acid*J 332.1 171.1 3.59 0.011 30 18 -
33 hydroxylysine*J 333.2 171.1 3.50 0.009 16 16 20
34 3-aminobutyric acid 274.1 171.1 3.67 0.009 10 20 6
35 cysteine 292.1 171.1 3.75 0.009 30 22 -
36 glutathione 478.0 171.1 3.76 0.009 30 38 -
J proline-d7 293.0 171.1 3.76 0.009 30 24 n/a
37 proline 286.1 116.1 3.79 0.009 30 50 6
38 3-aminoisobutyric acid*J 274.1 171.1 3.77 0.009 10 20
39 cystathionine*J 282.2 171.0 3.85 0.009 30 14 2
40 ornithine*J 303.1 171.1 3.86 0.009 60 22 20
41 epinephrine 354.1 171.1 3.93 0.009 30 22 -
42 2-aminoisobutyric acid 274.1 171.1 3.97 0.009 10 20 6
43 5-aminovaleric acid 288.1 171.1 3.98 0.009 30 16 -
44 octopamine 324.2 171.1 3.98 0.009 30 24 -
45 2-aminobutyric acid*K 274.1 171.1 4.07 0.009 10 20 6
46 cystine*K 291.1 171.1 4.08 0.009 10 12 n/q
K lysine-d4 246.1 171.1 4.10 0.020 30 14 n/a
47 lysine 244.2 171.1 4.10 0.020 30 12 2
48 putrescine 429.3 145.1 4.22 0.009 30 28 -
49 4-aminohippuric acid 365.2 171.0 4.36 0.019 6 36 -
50 3-hydroxytyramine 324.1 171.1 4.41 0.008 30 20 -
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(including single blank(s)). Interference was considered to be
present if a response ≥5.0%.
Stability. Stock solution stability of the underivatized
analytes at ambient temperature (6 h) or stored frozen at
−20 °C (48 h) was investigated. The stability of the derivatized
analytes (diluted 1:9 v/v with water) was also assessed by
storing the QC samples at ambient temperature (1 week) and
in the autosampler (diluted 1:99 v/v with water) and by
reanalysis of the QC samples maintained in the autosampler at
4 °C (36 h). For the analyte to be considered stable the
diﬀerence had to be within ±10% of the original value.
Data Analysis. The raw LC-MS data were processed by the
TargetLynx application package within MassLynx software
(Waters Corporation). The raw data was mean smoothed, and
peak integration was performed using ApexTrak algorithm.
Further statistical analysis was performed on the resulting
calculated concentrations (corrected for the 2-fold dilution of
the samples compared to the standard curve) using Prism,
where a Mann U Whitney test was applied to determine if
diﬀerences observed in concentrations between healthy
volunteers and patients with ALF were statistically signiﬁcant.
■ RESULTS AND DISCUSSION
Method Development. The AccQTag Ultra reagent reacts
with primary and secondary amines44−49 (illustrated in
supplementary Figure S1) to give derivatives with good
reversed-phase chromatographic and mass spectrometric
properties. Potential problems associated with the use of the
nonvolatile borate buﬀer combined with MS have previously
been discussed, and volatile alternative buﬀers have been
evaluated.43 However, probably as a result of large dilution
factor employed here, we encountered no buﬀer-related
problems, and no changes were made to the recommended
reaction conditions. Appropriate positive ESI MS conditions for
each of the analytes were obtained via direct infusion of the
individual derivatives, as detailed in Table 1 (columns 3, 4, 6, 7,
8 respectively). The AccQTag Ultra reagent gives rise to a
common fragment ion at m/z 171, generated by a loss of the
aminoquinoline (AMQ) moiety, and as can be seen from Table
1 (columns 3 and 4), in most cases, the combination of parent
ion and this common fragment was selected for detection.
While monoamines react to form a mono ACQ derivative
which ionizes in positive ESI to the [M+Acq+H]+ ion, some
polyamines (e.g., cystine, lysine) have multiple sites that can
form derivatives resulting in the addition of more than one
ACQ unit. The number of ACQ units is reﬂected in the charge
state of the analyte, and doubly derivatized compounds display
the most intense response. However, a smaller proportion of
the singly derivatized and singly charged and doubly derivatized
and singly charged ions are still detected. For example, for
cystine and lysine, the most abundant ions have m/z values of
291 and 244, respectively, corresponding to the [M+2xAcq
+2H]2+, while ions at m/z values of 581 ([M+2xAcq+H]+) and
411 ([M+1xAcq+H]+) for cystine and 487 ([M+2xAcq+H]+)
and 317 ([M+1xAcq+H]+) for lysine were observed at lower
abundances (for mass spectra, see supplementary Figure S2).
For quantiﬁcation, the most abundant transitions from each of
these precursor ions were used except for arginine, glycine and
proline where a more appropriate alternative transition was
selected due to matrix interferences. A chromatographic
method was then developed providing an analysis time of 7.5
min/sample (a mass chromatogram for a range of amino
compound standards is shown in Figure S3 and a similar mass
chromatogram for the isotopically labeled internal standards is
shown in Figure S4). The average peak width observed was 3 s
at the base giving a peak capacity of ca.120. The separation was
highly reproducible, with CVs for retention time (Table 1
column 5) for the ULOQ QC sample of <0.44%.
A number of the compounds determined in this assay are
isomers/isobars, for example, 1-methylhistidine and 3-methyl-
histidine; sarcosine, 3-aminopropanoic acid (β-alanine), and
alanine; 4-aminobutyric acid (GABA) acid, 2-aminoisobutyric
Table 1. continued
no. compound parent (m/z) fragment (m/z) RT (min) dwell time (s) cone voltage (V) collision energy (eV) LLOQ (μM)a
51 tyrosine*M 352.1 171.1 4.41 0.017 30 24 2
52 3-hydroxykynurenic acid 395.2 171.0 4.57 0.009 60 28 -
L methionine-13C5,15N 326.2 171.0 4.59 0.017 30 22 n/a
53 methionine 320.1 171.1 4.59 0.017 30 22 2
M valine-d8 296.1 171.1 4.61 0.017 30 20 n/a
54 homocysteine 306.0 171.1 4.62 0.017 30 20 -
55 valine 288.1 171.1 4.64 0.017 30 16 2
56 tyramine 308.1 171.1 4.82 0.017 30 24 -
57 N-methyl-L-valine 302.0 171.1 4.84 0.017 54 26 -
58 homocystine 439.1 171.1 4.87 0.009 10 24 -
59 3-hydroxyanthranilic acid 324.2 171.1 4.88 0.017 52 20 -
N isoleucine-d10 312.1 171.0 5.16 0.024 30 20 n/a
60 isoleucine 302.1 171.1 5.22 0.024 30 20 2
O leucine-d10 312.1 171.0 5.26 0.024 30 20 n/a
61 O-phosphoethanolamine 312.1 116.1 5.26 0.024 8 50 -
62 leucine 302.1 171.1 5.26 0.024 30 20 2
P phenylalanine-d5 341.1 171.1 5.44 0.024 30 22 n/a
63 phenylalanine 336.1 171.1 5.46 0.024 30 22 2
64 tryptophan*P 375.1 171.1 5.51 0.024 30 26 2
65 tryptamine 331.1 171.1 5.86 0.069 30 28 -
aNormal font − validated against stable-isotope-labeled IS of the same structure; normal font* − validated against a stable-isotope-labeled IS of a
diﬀerent structure (indicated by letter after *) but similar retention time; italic font − not validated but monitored; bold font − stable-isotope-
labeled IS. bBased on a 10 μL plasma or serum sample.
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acid and 2-aminobutyric acid; isoleucine and leucine; however,
all were resolved by the chromatographic method (illustrated in
Figure S5).
Sample preparation was investigated on the basis of either
protein precipitation with sulphosalicylic acid or various organic
solvents (acetonitrile, methanol and isopropanol), with or
without acidiﬁcation using 1% v/v formic acid. This led to the
selection solvent precipitation with two volumes of isopropa-
nol, containing 1% v/v formic acid, to one of diluted plasma/
serum sample based on better sensitivity and reduced matrix
eﬀects compared to, for example, methanol, sulphosalicylic acid,
among others (data not shown).
Method Validation. Following the development of a
suitable UHPLC-MS/MS system, the suitability of the method
for the analysis of amino compounds was then evaluated for
selected analytes (Table 1). In the absence of true biological
blank samples, standard curves and QC samples were prepared
in 50:50 water/methanol (v/v). A range of analytical attributes
were investigated, including linearity, lower and upper limits of
quantiﬁcation (LLOQ, ULOQ), intra- and interday accuracy
and precision, speciﬁcity, carryover, recovery, matrix and other
interferences, and analyte and derivative stability. Standard
curves were found to be linear over the range measured 1−400
μM, with correlation coeﬃcients (R) of 0.993 or better as
determined over the 3 days of the validation (Supplementary
Data Table S2). The concentration range covered by the
standard curve equates, in this instance, to 2−800 μM for
plasma/serum due to the 1:1 dilution of the samples prior to
Figure 2. Scaled SRM chromatogram of an ALF (A) and a control (B) subject, respectively.
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protein precipitation. The underivatized analytes were stable for
6 h at ambient temperature or frozen at −20 °C for 48 h
(Supplementary Data Tables S3 and S4, respectively). Similarly,
the derivatized analytes were also stable at ambient temperature
and in the autosampler at 4 °C for up to 1 week (1 week
stability data are provided in Supplementary Tables S5 and S6,
respectively). Carryover was 11% or less for all of the analytes
tested, whereas that of the ISs was less than 1%.
The intra- and interday performance of the assay was
evaluated by the analysis of samples on three separate occasions
on three separate days over the concentration range of 2−800
μM, and the method was found to be reproducible and
accurate. For both intra- and interday analysis a LLOQ of 2 μM
was obtained for 18 of the amino acids (summarized in Table
1). A further 8 of the target analytes (ethanolamine, histidine,
proline, serine, 2-aminoisobutyric acid, citrulline, and 2-
aminobutyric acid and 4-aminobutyric acid (GABA)) gave
acceptable results results using a LLOQ of 6 μM, whereas an
additional 7 compounds (arginine, carnosine, glycine, 3-
methylhistidine, 1-methylhistidine, hydroxylysine, and orni-
thine) could be quantiﬁed using LLOQs of 20 μM. The ULOQ
for all analytes was 800 μM. A summary of the validated
analytical ranges for these analytes is provided in Supple-
mentary Table S7.
The intra- and interday precision of the assay was determined
by examining the CVs of the QC standards for each of the
analytes and ranged from 0.91 to 16.9% for the intraday
determinations and 2.10−15.9% for the interday comparison.
The corresponding ﬁgures for intra- and interday accuracy were
0.05−15.6 and 0.78−13.7%, respectively. Mean intra- and
interday bias were calculated to be 0.04−16.4% and 0.04−
12.5%, respectively. The mean interday concentration and
precision data are provided in Table S8. Speciﬁcity, in terms of
matrix and other interferences was assessed for matrix-to-
analyte (at the LLOQ), matrix-to-internal standard, analyte-to-
internal standard, and internal standard-to-analyte interference.
Both matrix-to-analyte and matrix-to-internal standard were
≤20%. In the case of internal standard-to-analyte (at the
LLOQ), the acceptance criterion of ≤20% was met in all cases
except for glycine-d5. This IS is eﬀectively glycine-d2 as 3 of the
deuterium atoms are exchangeable with water protons on
dissolution and, in this instance, the 2 mass unit diﬀerence
between analyte and IS was insuﬃcient to ensure speciﬁcity and
resulted in internal standard-to-analyte interference. Replace-
ment of glycine-d5 with the alternative IS glycine-
13C2
15N d2
should eliminate this issue. All of the analytes gave values of
≤5% when analyte-to-IS interference was investigated except
for glycine and glutamine.
Figure 3. Amino acid concentrations (log μM) in control (blue) and ALF (red) subjects, box plots; bar, median; box, interquartile range; whiskers,
upper and lower values. A two-tailed Mann−Whitney U test was applied to test for statistical signiﬁcance, p-values for these are denoted by **** p <
0.0001; *** < 0.001; ** < 0.01; * < 0.1.
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The stable-isotope-labeled compounds used as internal
standards were used to assess gross matrix interferences
following spiking into six diﬀerent human plasma and serum
samples. While diﬀerences were noted matrix matrix interfer-
ences were generally ≤20%.
Analyte recoveries, as determined using stable-isotope-
labeled ISs spiked into plasma and serum, were high and
repeatable (74−78 and 93−101% respectively at 3 μM)
(Supplementary Table S9), as would be expected for a method
with minimal sample preparation,
Application to Human Subjects. Following validation,
the method was then applied to the analysis of samples
obtained from patients suﬀering from acute liver failure and
normal healthy controls. ALF is characterized by a rapid decline
in liver function following a catastrophic insult to the liver (e.g.,
acetaminophen overdose or viral hepatitis). The liver plays a
major role in amino acid metabolism and is central to the
regulation of metabolic pathways.53 In liver disease, these
pathways are known to be aﬀected by depletion of the branched
chain amino acids, including valine, leucine, and isoleucine, and
increased concentrations of aromatic amino acids, including
phenylalanine and tyrosine (the Fischer ratio).54 Perturbation
of the urea cycle and a limited capacity for detoxiﬁcation of
ammonia with glutamine are associated with acute liver failure
and in particular with hepatic encephalopathy, although the
mechanism and prognostic signiﬁcance remains unclear.
Application of the methodology described above to plasma
samples derived from healthy controls (n = 40) and patients
with APAP-induced ALF (n = 14) revealed changes in 15
amino compounds that were subject to quantiﬁcation. Changes
were also noted in the relative amounts of aminoadipic acid, 3-
aminopropanoic acid, 2-aminoisobutyric acid, cysteine, cys-
tathionine, homoserine, histidine, hydroxylysine, 3-methylhisti-
dine, and 4-aminobutyric acid (GABA) (Zia et al, in
preparation). Selected ion chromatograms for a “typical”
control and ALF subject are shown in Figure 2. As expected,
signiﬁcantly elevated concentrations of phenylalanine and
tyrosine were observed in the ALF group with mean
concentrations of phenylalanine in controls of 65 μM compared
to 245 μM in ALF, whereas for tyrosine, the concentrations
were 69 versus 191 μM in controls and patients, respectively
(Figure 3). In the case of isoleucine, concentrations were
reduced from 76 μM in control subjects to 56 μM in patients,
whereas valine concentrations declined from 234 μM in
controls to 188 μM in patients. Changes were also seen for
glutamine and glycine, which were elevated in ALF, with the
former rising from 427 μM to 1123 μM and the latter from 249
μM to 693 μM in patients (see Figure 3). Further results for
quantiﬁable amino compounds are provided in Supplementary
Figure S6. Eﬀects were also noted on sarcosine with this analyte
not detected in controls but observable with concentrations
over the range 2.4−7.2 μM in ALF patients. Changes were also
noted in the relative amounts of aminoadipic acid, β-alanine, β-
amino-iso-butyric acid, cysteine, cystathionine, homoserine,
histidine, hydroxylysine, 3-methylhistidine, and γ-amino-n-
butyric acid; however, while detectable, these compounds
were below the limits of quantiﬁcation (data not shown).
Furthermore, a 6-fold increase was observed for 5-aminovaleric
acid in ALF patients relative to controls (compound 43, see
Table 1), an amino compound which was subject to monitoring
but not quantiﬁcation in the current method. As well as
conﬁrming the known eﬀects of ALF, such as the expected
changes in aromatic and branched chain amino acids, the
application of this UPLC-MS method has illustrated changes in
the amounts of other amino-containing compounds in response
to liver injury, including the previously unreported eﬀects on
plasma sarcosine concentrations.
■ CONCLUSIONS
The use of 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate
(AccQTag UltraTM) for the targeted analysis of amino-
containing compounds provides stable derivatives with good
RPLC and MS properties. These derivatives enable the
sensitive, reproducible and speciﬁc analysis of these compounds
in human serum and plasma, requiring only 10 μL of sample,
and the short analysis time makes the methodology attractive
for high throughput targeted UPLC-ESI-MS/MS analysis.
While conﬁrming previous observations application of the
method also revealed novel increases in sarcosine concen-
trations in patients with ALF as a result of APAP overdose. This
methodology should be of great beneﬁt in supporting metabolic
phenotyping studies in epidemiological and clinical environ-
ments.
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